Trial · NCT04837131
Outcomes15
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 15 of 15
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Treatment-emergent Adverse Event (AE) | 7 months | Participants | COUNT_OF_PARTICIPANTS | |
| PRIMARY | Adverse Events Leading to Ixazomib Dose Modifications | 7 months | Participants | COUNT_OF_PARTICIPANTS | |
| PRIMARY | Adverse Events Leading to Ixazomib Early Discontinuation | 7 months | Participants | COUNT_OF_PARTICIPANTS | |
| PRIMARY | Change in the UCLA Scleroderma Clinical Trials Consortium Gastrointestinal 2.0 (UCLA SCTC GIT 2.0) Questionnaire Score | Baseline, 7 months | score on a scale | MEAN | |
| SECONDARY | Change From Baseline in Modified Rodnan Skin Score (MRSS) | Baseline, 24 weeks | score on a scale | MEAN | |
| SECONDARY | Change From Baseline in High Resolution Chest CT Scan Goh Score | Baseline, 24 weeks | Chest CT scan not performed on any participants. Data not collected nor analyzed as study was terminated due to low enrollment. | ||
| SECONDARY | Change in Forced Vital Capacity (FVC) % Predicted. | Baseline, 7 months | percentage of air | MEAN | |
| SECONDARY | Change in Total Lung Capacity (TLC) % Predicted | Baseline, 24 weeks | percentage of air in lungs | MEAN | |
| SECONDARY | Severity of Dyspnea at Baseline (Mahler Baseline Dyspnea Index) | Baseline | Mahler Baseline Dyspnea Index was not completed by any subject. Data not collected nor analyzed as study was terminated due to low enrollment. | ||
| SECONDARY | Dyspnea Status Rating (Mahler Transitional Dyspnea Index) | 12 weeks, 24 weeks | Mahler Transitional Dyspnea Index was not completed by any subject. Data not collected nor analyzed as study was terminated due to low enrollment. | ||
| SECONDARY | Change in Scleroderma Health Assessment Questionnaire (SHAQ) Score | Baseline, 24 weeks | Scleroderma Health Assessment Questionnaire was not completed by any subject. Data not collected nor analyzed as study was terminated due to low enrollment. | ||
| SECONDARY | Change in Patient Global Assessment of Disease Activity (PtGA) | Baseline, 24 weeks | score on a scale | MEAN | |
| SECONDARY | Change in Physician Global Assessment of Disease Activity (MDGA) | Baseline, 24 weeks | score on a scale | MEAN | |
| SECONDARY | Change in American College of Rheumatology Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis (ACR CRISS) | Baseline, 24 weeks | American College of Rheumatology Composite Response Index testing was not completed by any subject. Data not collected nor analyzed as study was terminated due to low enrollment. | ||
| SECONDARY | Change in Diffusion Capacity (DLCO) % Predicated | Baseline, 7 months | percentage of carbon monoxide | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04837131/outcomes